Research programme: breast and ovarian cancer vaccine - IDM PharmaAlternative Names: Breast and ovarian cancer vaccines research programme - Epimmune
Latest Information Update: 05 Sep 2007
At a glance
- Originator IDM Pharma; University of Washington
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Breast cancer; Ovarian cancer
Most Recent Events
- 05 Sep 2007 Discontinued - Preclinical for Ovarian cancer in USA (unspecified route)
- 05 Sep 2007 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma